Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2263-2268

  Torzewski, Michael ^a   Sarbia, Mario ^a   Verreet, Patrick ^a   Dutkowski, Philipp ^b   Heep, Hansjörg ^a   Willers, Reinhart ^a   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION FUNCTION; DIAGNOSTIC VALUE; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CYTOPLASM; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031426780     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Liotta, L. A., Rao, C. N., and Barsky, S. H. Tumor invasion and the extracellular matrix. Lab. Invest., 49: 636-649, 1983.
2. Gabbert, H. Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev., 4: 293-309, 1985.
3. Liotta, L. A., Steeg, P. S., Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
4. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
5. Blasi, F., Vassalli, J. D., and Dano, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-804, 1987.
6. Tryggvason, K., Hoyhtya, M., Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.
7. Hekman, C. M., and Loskutoff, D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem., 260: 11581-11587, 1985.
8. 2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem., 265: 6453-6460, 1990.
9. Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., Appella, E., and Blasi, F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell-surface, plasmin-dependent proteolysis. EMBO J., 9: 467-474, 1990.
10. Dano, K., Behrendt, N., Brünner, N., Ellis, V., Ploug, M., and Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8 (Suppl. 1): 189-203, 1994.
11. Estreicher, A., Mühlhauser, J., Carpentier, J. R., Orci, L., and Vassalli, J. D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol., 111: 783-792, 1990.
12. Cubellis, M. V., Wun, T. C., and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9: 1079-1085, 1990.
13. Bouchet, C., Spyratos, F., Martin, P. M., Hacene, K., Gentile, A., and Oglobine, J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer, 69: 398-405, 1994.
14. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H. E., Becker, K., Roder, J. D., Fink, U., and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
15. Sato, T., Nishimura, G., Yonemura, Y., Nojima, N., Ninomiya, I., Fujimura, T., Sugiyama, K., Miwa, K., Miyazaki, I., Nonomura, A., and Yagamuchi, Y. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology, 52: 347-352, 1995.
16. Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., Schmitt, M., Jänicke, F., Höfler, H., and Graeff, H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55: 3958-3963, 1995.
17. Kobayashi, H., Fujishiro, S., and Terao, T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res., 54: 6539-6548, 1994.
18. de Vries, T. J., Quax, P. H., Denijin, M., Verijp, K. N., Verheijen, J. H., Verspaget, H. W., Weidle, U. H., Ruiter, D. J., and van Muijen, G. N., Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol., 144: 70-81, 1994.
19. Choong, P. F. M., Fernö, M., Akerman, M., Willen, H., Langström, E., Gustafson, P., Alvegard, T., and Rydholm, A. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer, 69: 268-272, 1996.
20. Nishino, N., Aoki, K., Tokura, Y., Sakaguchi, S., Takada, Y., and Takada, A. The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb. Res., 50: 527-535, 1988.
21. Sier, C. F. M., Fellbaum, C., Verspaget, H. W., Schmitt, M., Griffioen, G., Graeff, H., Höfler, H., and Lamers, C. B. H. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology, 19: 231-237, 1991.
22. Hewin, D. F., Savage, P. B., Alderson, D., and Vipond, M. N. Plasminogen activators in oesophageal carcinoma. Br. J. Surg., 83: 1152-1155, 1996.
23. International Union Against Cancer. TNM Classification of Malignant Tumours, 4th Ed., 2nd revision. Berlin: Springer-Verlag, 1992.
24. WHO. Histological typing of oesophageal and gastric tumours, 2nd Ed. Berlin: Springer-Verlag, 1990.
25. Sarbia, M., Porschen, R., Borchard, F., Horstmann, O., Willers, R., and Gabbert, H. E. Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinomas of the esophagus. Int. J. Cancer, 61: 333-336, 1995.
26. Sarbia, M., Bittinger, F., Porschen, R., Dutkowski, P., Willers, R., and Gabbert, H. E. Prognostic value of histopathologic parameters of esophageal squamous cell carcinoma. Cancer (Phila.), 76: 922-927, 1995.
27. Wagner, S. N., Atkinson, M. J., Thanner, S., Wagner, C., Schmitt, M., Wilhelm, O., Rotter, M., and Höfler, H. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am. J. Pathol., 147: 183-192, 1995.
28. Parolini, S., Flagiello, D., Cinquetti, A., Gozzi, R., Cristini, S., Capiello, J., Nicolai, P., Rusnati, M., Presta, M., and Molinari Tosatti, M. P. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br. J. Cancer, 74: 1168-1174, 1996.
29. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
30. Duffy, M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis, 10: 145-155, 1992.
31. Yonemura, Y., Nojima, N., Kaji, M., Fujimura, T., Itoh, H., Ninomiya, I., Miyazaki, I., Endo, Y., and Sasaki, T. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer (Phila.), 76: 941-953, 1995.
32. Kohga, S., Harvey, S., and Markus, G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res., 45: 1787-1796, 1985.
33. Oka, T., Ishida, T., Nishino, T., and Sugimachi, K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinomas. Cancer Res., 51: 3522-3525, 1991.
34. Takai, S., Yamamura, M., Tanaka, K., Kawanishi, H., Tsuji, M., Nakane, Y., Hioki, K., and Yamamoto, M. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int. J. Cancer, 48: 20-27, 1991.
35. Jankun, J., Merrick, H. W., Goldblatt, P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell. Biochem., 53: 135-144, 1993.
36. Niiya, K., Shinbo, M., Ozawa, T., Hayakawa, Y., and Sakuragawa, N. Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8. Thromb. Haemostasis, 74: 1511-1515, 1995.
37. Murphy, P., and Hart, D. A. Modulation of plasminogen activator and plasminogen activator inhibitor expression in the human U373 glioblastoma/astrocytoma cell line by inflammatory mediators. Exp. Cell Res., 198: 93-100, 1992.
38. Tran-Thang, C., Kruithof, E., Lahm, H., Schuster, W. A., Tada, M., and Sordat, B. Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. Br. J. Cancer, 74: 846-852, 1996.
39. Arndt, A., Murphy, P., and Hart, D. A. Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. Biochim. Biophys. Acta, 1138: 149-156, 1992.
40. Carlomagno, C., Perrone, F., Lauria, R., de Laurentiis, M., Gallo, C., Morabito, A., Pettinato, G., Panico, L., Bellelli, T., Apicella, A., Petrella, G., Bianco, A. R., and de Placido, S. Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology, 52: 272-277, 1995.
41. Kainz, C. H., Gitsch, G., Tempfer, C., Heinzl, H., Koelbl, H., Breitecker, G., and Reinthaller, A. Vascular space invasion and inflammatory stromal reaction as prognostic factors in patients with surgically treated cervical cancer stage IB to IIB. Anticancer Res., 14: 2245-2248, 1994.
42. Blackwell, K. E., Fu, Y-S., Calcaterra, T. C. Laryngeal Dysplasia. Cancer (Phila.), 75: 457-463, 1995.
43. Mori, M., Shimono, R., Kido, A., Kuwano, H., Akazawa, K., and Sugimachi, K. Distribution of basement membrane antigens in human esophageal lesions: an immunohistochemical study. Int. J. Cancer, 47: 839-842, 1991.
44. Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., Andersons, P. B., Kristensens, P., and Dano, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 752-757, 1984.
45. Gaylis, F. D., Keer, H. D., Wilson, M. J., Kwaan, H. C., Sinha, A. A., and Kozlowski, J. M. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J. Urol., 142: 193-198, 1989.
46. Delbaldo, C., Cunningham, M., Vassalli, J-D., and Sappino, A-P. Plasmin-catalyzed proteolysis in colorectal neoplasia. Cancer Res., 55: 4688-4695, 1995.